MUMBAI, India, July 30 -- Intellectual Property India has published a patent application (202641088060 A) filed by Dr. M. Sangeetha; and Dr. V. Uma Maheswara Rao on July 19, 2026, for A Multi-Mechanism Monoclonal Antibody Composition With Enhanced Pharmacokinetics And Stability.
Inventors include Dr. N. Madhavi; Mrs. G. Supriya; Mr. Roshan Ali; and Mrs. Lahari.
The application for the patent was published on July 24, 2026, under issue no. 30/2026.
Abstract: A multi-mechanism monoclonal antibody composition with enhanced pharmacokinetics and stability is disclosed. The system comprises a monoclonal antibody having an Fc region engineered for increased binding to neonatal Fc receptor (FcRn) to extend systemic circulation, a biodegradable carrier matrix configured to provide sustained release following subcutaneous administration, and a reversible protective modification associated with the antibody to improve storage stability and reduce degradation. The combined system enables dual pharmacokinetic control through both prolonged systemic half-life and controlled release of the antibody over an extended period. The reversible protective modification is configured to undergo activation or removal under physiological conditions, thereby restoring antibody activity post-administration. The composition facilitates reduced dosing frequency and improved therapeutic efficacy, particularly for treatment of chronic conditions such as autoimmune disorders.
Disclaimer: Curated by HT Syndication.
